Table of Content

1. Introduction To STAT3 Inhibitors


2. STAT3 Inhibition Approaches
2.1 Direct Inhibition
2.2 Indirect Inhibition


3. Role Of STAT3 Inhibitors In Cancers
3.1 Breast Cancer
3.2 Pancreatic Cancer
3.3 Lung Cancer
3.4 Melanoma
3.5 Lymphoma


4. Therapeutic Approaches For STAT3 Inhibition
4.1 Targeted Therapy With STAT3 Inhibitors
4.2 Monotherapy With STAT3 Inhibitors
4.3 Combination Therapies With STAT3 Inhibitors


5. Global STAT3 Inhibitors Market Outlook


6. Global STAT3 Inhibitors Clinical Pipeline Overview
6.1 By Country
6.2 By Indication
6.3 By Organization
6.4 By Phase


7. Global STAT3 Inhibitors Clinical Pipeline By Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
7.8 Preregistration


8. Marketed STAT3 Inhibitor Drug Clinical & Patent Insight


9. STAT3 Inhibitors Market Dynamics
9.1 Drivers & Opportunities
9.2 Challenges & Restraints


10. Competitive Landscape
10.1 ABM Therapeutics
10.2 Accendatech
10.3 Baylor College of Medicine
10.4 C&C Research Laboratories
10.5 Daewoong Pharmaceutical
10.6 First Wave BioPharma
10.7 GLG Pharma
10.8 Hanlim Pharmaceutical
10.9 Immix Biopharma
10.10 Institut Pasteur Korea
10.11 Ionis Pharmaceuticals
10.12 Jiangsu Hengrui Medicine Co.
10.13 Kymera Therapeutics
10.14 NeuroBo Pharmaceuticals
10.15 NovoMedix
10.16 Phytoption
10.17 Rock Creek Pharmaceuticals
10.18 Singh Biotechnology
10.19 Sumitomo Pharma
10.20 TFF Pharmaceuticals
10.21 Tvardi Therapeutics
10.22 UNION Therapeutics
10.23 University of Texas M. D. Anderson Cancer Center
10.24 Verta



List of Figures

Figure 1-1: Structure Of STAT3 & STAT3-STAT3 Dimer
Figure 1-2: Structure Of Stattic
Figure 1-3: STAT3 Inhibitors - Development Timeline

Figure 2-1: Classification Of STAT3 Inhibitors Based On Type
Figure 2-2: Advantages & Disadvantages Of Peptide-Based Inhibitors
Figure 2-3: Napabucasin - Mechanism Of Action
Figure 2-4: Direct & Indirect Mechanisms Of STAT3 Inhibition

Figure 3-1: Global - Estimated Breast Cancer Incidences & Deaths (Millions), 2020
Figure 3-2: US - Estimated Breast Cancer Incidences (Thousands), 2022
Figure 3-3: US - Estimated Breast Cancer Deaths (Thousands), 2022
Figure 3-4: STAT3-Associated Pathways In Breast Cancer Treatment Resistance
Figure 3-5: Investigative STAT3 Inhibitors For Breast Cancer
Figure 3-6: Global - Estimated Pancreatic Cancer Incidences & Deaths (Thousands), 2020
Figure 3-7: US - Estimated Pancreatic Cancer Cases & Deaths (Thousands), 2022
Figure 3-8: Investigative STAT3 Inhibitors For Pancreatic Cancer
Figure 3-9: Global - Estimated Lung Cancer Incidences & Deaths (Millions), 2020
Figure 3-10: US - Estimated Lung Cancer Cases & Deaths (?000), 2022
Figure 3-11: Effects of STAT3 Hyperactivation
Figure 3-12: Investigative STAT3 Inhibitors For Lung Cancer
Figure 3-13: Global - Estimated Melanoma Incidences & Deaths (Thousands), 2020
Figure 3-14: US - Estimated Melanoma Cases & Deaths (Thousands), 2022
Figure 3-15: Investigative STAT3 Inhibitors For Melanoma
Figure 3-16: Global - Estimated Lymphoma Incidences & Deaths (Thousands), 2020
Figure 3-17: US - Estimated Lymphoma Cases & Deaths (Thousands), 2022
Figure 3-18: Causes & Effects Of Dysregulated STAT3 Signaling
Figure 3-19: Some Investigative Drugs For Lymphoma & Their Targets

Figure 4-1: Mechanism Of Action Of EGFR Inhibitors

Figure 5-1: Global – STAT3 Inhibitor Drug Market Forecast (US$ Million), 2024 & 2028

Figure 6-1: Global – Number Of STAT3 Inhibitors Clinical Trials By Country, 2023 Till 2028
Figure 6-2: Global – Number Of STAT3 Inhibitors Clinical Trials By Indication, 2023 Till 2028
Figure 6-3: Global – Number Of STAT3 Inhibitors Clinical Trials By Organization, 2023 Till 2028
Figure 6-4: Global – Number Of STAT3 Inhibitors Clinical Trials By Phase, 2023 Till 2028

Figure 9-1: STAT3 Inhibitors Market Drivers
Figure 9-2: Challenges for STAT3 Inhibitors Market